Management of RAASi-associated hyperkalemia in patients with cardiovascular disease

Renin–angiotensin–aldosterone system inhibitors (RAASi) reduce morbidity and mortality in heart failure (HF) with reduced ejection fraction in a dose-dependent manner. They also have a positive impact in other cardiovascular diseases (CVDs). However, RAASi may induce hyperkalemia, a potentially life...

Full description

Bibliographic Details
Main Author: Silva-Cardoso, José (author)
Other Authors: Brito, Dulce (author), Frazão, João Miguel (author), Ferreira, Aníbal (author), Bettencourt, Paulo (author), Branco, Patrícia (author), Fonseca, Cândida (author)
Format: review
Language:eng
Published: 2021
Subjects:
Heart failure with reduced ejection fraction
Hyperkalemia
Novel potassium binders
RAASi optimization
Renin–angiotensin–aldosterone system inhibitors
Cardiology and Cardiovascular Medicine
SDG 3 - Good Health and Well-being
Online Access:http://hdl.handle.net/10362/113799
Country:Portugal
Oai:oai:run.unl.pt:10362/113799

Internet

http://hdl.handle.net/10362/113799

Similar Items